score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.4209	297.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0.0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				NRAS p.Q61L (Missense)	1.0	MEL-IPI_Pat139	MEL-IPI_Pat139-Tumor-SM-5VWJH	MEL-IPI_Pat139-Normal-SM-5VWHY
Putatively Actionable	Preclinical			Copy Number	MDM2	Amplification				0.0	0.0		Putatively Actionable	nutlin-3	MDM2-p53 inhibition	Targeted therapy	Presence of amplified MDM2 may suggest sensitivity to nutlin-3 in the absense of mutant TP53.	Endo S, Yamato K, Hirai S, et al. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Cancer Sci. 2011;102(3):605-13.	https://doi.org/10.1111/j.1349-7006.2010.01821.x													0				MDM2 Amplification	0.0	MEL-IPI_Pat139	MEL-IPI_Pat139-Tumor-SM-5VWJH	
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.S461F	0.8113	53.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf													0				PDGFRA p.S461F (Missense)	0.0	MEL-IPI_Pat139	MEL-IPI_Pat139-Tumor-SM-5VWJH	MEL-IPI_Pat139-Normal-SM-5VWHY
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.I55V	0.415	306.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0.0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				NRAS p.I55V (Missense)	1.0	MEL-IPI_Pat139	MEL-IPI_Pat139-Tumor-SM-5VWJH	MEL-IPI_Pat139-Normal-SM-5VWHY
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat139		
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.L1038F	0.4527	402.0	0.0	0.0																Investigate Actionability	1.0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				SF3B1 p.L1038F (Missense)		MEL-IPI_Pat139	MEL-IPI_Pat139-Tumor-SM-5VWJH	MEL-IPI_Pat139-Normal-SM-5VWHY
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.V571A	0.4103	117.0	0.0	0.0																Investigate Actionability	1.0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				SF3B1 p.V571A (Missense)		MEL-IPI_Pat139	MEL-IPI_Pat139-Tumor-SM-5VWJH	MEL-IPI_Pat139-Normal-SM-5VWHY
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.E850K	0.7619	21.0	0.0	0.0																Investigate Actionability	0.0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				SETBP1 p.E850K (Missense)		MEL-IPI_Pat139	MEL-IPI_Pat139-Tumor-SM-5VWJH	MEL-IPI_Pat139-Normal-SM-5VWHY
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat139		
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.S1060F	0.4714	70.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098													0				SMARCA4 p.S1060F (Missense)		MEL-IPI_Pat139	MEL-IPI_Pat139-Tumor-SM-5VWJH	MEL-IPI_Pat139-Normal-SM-5VWHY
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.P148T	0.527	315.0	0.0	0.0																Investigate Actionability	0.0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				ASXL1 p.P148T (Missense)		MEL-IPI_Pat139	MEL-IPI_Pat139-Tumor-SM-5VWJH	MEL-IPI_Pat139-Normal-SM-5VWHY
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.R686C	0.2394	71.0	8e-06	0.0																					0				NTRK1 p.R686C (Missense)		MEL-IPI_Pat139	MEL-IPI_Pat139-Tumor-SM-5VWJH	MEL-IPI_Pat139-Normal-SM-5VWHY
Biologically Relevant				Somatic Variant	EPCAM	Missense	p.D206N	0.42200000000000004	218.0	4.9e-05	0.0																					0				EPCAM p.D206N (Missense)		MEL-IPI_Pat139	MEL-IPI_Pat139-Tumor-SM-5VWJH	MEL-IPI_Pat139-Normal-SM-5VWHY
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.H549Y	0.5294	51.0	0.0	0.0																					0				RUNX1T1 p.H549Y (Missense)		MEL-IPI_Pat139	MEL-IPI_Pat139-Tumor-SM-5VWJH	MEL-IPI_Pat139-Normal-SM-5VWHY
Biologically Relevant				Somatic Variant	RUNX1T1	Nonsense	p.R316*	0.5806	217.0	0.0	0.0																					0				RUNX1T1 p.R316* (Nonsense)		MEL-IPI_Pat139	MEL-IPI_Pat139-Tumor-SM-5VWJH	MEL-IPI_Pat139-Normal-SM-5VWHY
Biologically Relevant				Somatic Variant	AURKB	Missense	p.E114K	0.878	41.0	0.0	0.0																					0				AURKB p.E114K (Missense)		MEL-IPI_Pat139	MEL-IPI_Pat139-Tumor-SM-5VWJH	MEL-IPI_Pat139-Normal-SM-5VWHY
Biologically Relevant				Somatic Variant	NF1	Missense	p.S2132F	0.4619	210.0	0.0	0.0																					0				NF1 p.S2132F (Missense)		MEL-IPI_Pat139	MEL-IPI_Pat139-Tumor-SM-5VWJH	MEL-IPI_Pat139-Normal-SM-5VWHY
Biologically Relevant				Copy Number	TMPRSS2	Amplification				0.0	0.0																					0				TMPRSS2 Amplification		MEL-IPI_Pat139	MEL-IPI_Pat139-Tumor-SM-5VWJH	
Biologically Relevant				Copy Number	EWSR1	Amplification				0.0	0.0																					0				EWSR1 Amplification		MEL-IPI_Pat139	MEL-IPI_Pat139-Tumor-SM-5VWJH	
Biologically Relevant				Copy Number	TET2	Deletion				0.0	0.0																					0				TET2 Deletion		MEL-IPI_Pat139	MEL-IPI_Pat139-Tumor-SM-5VWJH	
Biologically Relevant				Copy Number	KRAS	Deletion				0.0	0.0																					0				KRAS Deletion		MEL-IPI_Pat139	MEL-IPI_Pat139-Tumor-SM-5VWJH	
Biologically Relevant				Copy Number	SETBP1	Deletion				0.0	0.0																					0				SETBP1 Deletion		MEL-IPI_Pat139	MEL-IPI_Pat139-Tumor-SM-5VWJH	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion)		MEL-IPI_Pat139		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.907																									0				COSMIC Signature (version 2) 7 (91%)		MEL-IPI_Pat139		
